Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Lee

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|April 22, 2024
Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testingJay M Lee
Thoracic Surgery Clinics|November 19, 2025
Neoadjuvant ImmunotherapyJay M Lee
JAMA Oncology|August 1, 2024
Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung CarcinomaJay M Lee
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2022
DiscussionJay M Lee
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2022
Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet needJay M Lee
Journal of Thoracic Disease|January 10, 2017
Limited resection versus lobectomy in early-stage non-small cell lung cancerPaul A Toste, Jay M Lee
Cancer Treatment and Research|August 19, 2016
Surgical Treatment of Lung CancerOsita I Onugha, Jay M Lee
Journal of Thoracic Disease|April 3, 2018
Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trialsSha'Shonda L Revels, Jay M Lee
Annals of Translational Medicine|October 29, 2019
VATS lobectomy for early lung cancer: long-term outcomesPaul A Toste, Jay M Lee
Translational Lung Cancer Research|January 24, 2022
Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpointClaire M Faltermeier, Jay M Lee
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
The Journal of Thoracic and Cardiovascular Surgery|April 22, 2024
Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testingJay M Lee
Thoracic Surgery Clinics|November 19, 2025
Neoadjuvant ImmunotherapyJay M Lee
JAMA Oncology|August 1, 2024
Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung CarcinomaJay M Lee
The Journal of Thoracic and Cardiovascular Surgery|August 26, 2022
DiscussionJay M Lee
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2022
Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet needJay M Lee
Journal of Thoracic Disease|January 10, 2017
Limited resection versus lobectomy in early-stage non-small cell lung cancerPaul A Toste, Jay M Lee
Cancer Treatment and Research|August 19, 2016
Surgical Treatment of Lung CancerOsita I Onugha, Jay M Lee
Journal of Thoracic Disease|April 3, 2018
Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trialsSha'Shonda L Revels, Jay M Lee
Annals of Translational Medicine|October 29, 2019
VATS lobectomy for early lung cancer: long-term outcomesPaul A Toste, Jay M Lee
Translational Lung Cancer Research|January 24, 2022
Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpointClaire M Faltermeier, Jay M Lee
Pageof 10